Fate Therapeutics (FATE)

$1.08 +0.06 (5.88%)
Market Cap 123.43M
Revenue (ttm) 13.63M
Net Income (ttm) -186.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,366.54%
Debt to Equity Ratio 0.00
Volume 1,494,100
Avg Vol 1,497,490
Day's Range N/A - N/A
Shares Out 115.35M
Stochastic %K 31%
Beta 2.22
Analysts Sell
Price Target $4.94

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus eryt...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 875 1800
Address:
12278 Scripps Summit Drive, San Diego, United States
Rocketman808
Rocketman808 Jan. 14 at 10:29 PM
$FATE always quiet before blast off. quietly doubled my position here today in several 25k lots. its go to time soon. this is going to have a big time run up
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Jan. 14 at 9:50 PM
$FATE $TCRX are doing better today
0 · Reply
cta7978
cta7978 Jan. 14 at 7:33 PM
$FATE
0 · Reply
GangsterX
GangsterX Jan. 14 at 3:22 PM
$PMVP $FATE These aren’t my favorites, but I believe they’re cheap given the current prices. I think the whale sold AI stocks and is now looking into small-cap undervalued stocks. It’s a slo, but I think it’ll move soon. mall bet here.
1 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Jan. 14 at 2:21 PM
$FATE and $TCRX both are way under cash. $XBI has moved up in last 2 months yet above two stocks not much gain so far.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 14 at 2:28 AM
$FATE This one's been bouncing around a bit lately. It hit a high around $1.70 and dipped to a low near $0.65. Currently holding steady around $1.02 with average volume around 1.9 million.
0 · Reply
Southshd
Southshd Jan. 13 at 8:05 PM
$FATE Grabbed another 25k shares today! 225k shares long and strong! 2026 could be a great year for bio stocks, several with decent balance sheets have already started to move in a positive direction. Holding 200k of Allo as well which has had a nice run the past few weeks hopefully Fate will follow! GL fellow longs!
1 · Reply
cta7978
cta7978 Jan. 13 at 2:55 PM
$FATE
1 · Reply
DarkSonar
DarkSonar Jan. 13 at 3:03 AM
$FATE This is a wonderful little stockity stock. Keep an eye on this because is primed for a move up!! 🧨
2 · Reply
Nik7777
Nik7777 Jan. 13 at 12:08 AM
$FATE https://www.marketbeat.com/instant-alerts/insider-selling-fate-therapeutics-nasdaqfate-insider-sells-10589-shares-of-stock-2026-01-12/#google_vignette
1 · Reply
Latest News on FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2026, 4:05 PM EST - 9 days ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 7 weeks ago

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13, 2025, 8:30 AM EST - 2 months ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Oct 26, 2025, 11:30 AM EDT - 2 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Aug 12, 2025, 4:01 PM EDT - 5 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Jun 11, 2025, 9:00 AM EDT - 7 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025, 4:30 PM EDT - 8 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 28, 2025, 5:54 PM EDT - 8 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025, 4:01 PM EDT - 8 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

May 8, 2025, 6:22 PM EDT - 8 months ago

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 29, 2025, 9:25 AM EDT - 9 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Apr 14, 2025, 8:00 AM EDT - 9 months ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 5, 2025, 4:01 PM EST - 11 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2025, 4:01 PM EST - 11 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 14, 2025, 4:01 PM EST - 11 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Feb 4, 2025, 7:41 PM EST - 1 year ago

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics Announces Leadership Transition

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 20, 2024, 4:34 PM EST - 1 year ago

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 11, 2024, 6:12 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 9, 2024, 8:30 AM EDT - 1 year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

May 3, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Apr 29, 2024, 4:48 PM EDT - 1 year ago

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 19, 2024, 8:44 AM EDT - 1 year ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Fate Therapeutics to Present at Upcoming March Investor Conferences

Mar 1, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 8:25 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 26, 2024, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics: Getting There, But Perpetually

Nov 12, 2023, 12:10 PM EST - 2 years ago

Fate Therapeutics: Getting There, But Perpetually

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 9:12 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Rocketman808
Rocketman808 Jan. 14 at 10:29 PM
$FATE always quiet before blast off. quietly doubled my position here today in several 25k lots. its go to time soon. this is going to have a big time run up
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Jan. 14 at 9:50 PM
$FATE $TCRX are doing better today
0 · Reply
cta7978
cta7978 Jan. 14 at 7:33 PM
$FATE
0 · Reply
GangsterX
GangsterX Jan. 14 at 3:22 PM
$PMVP $FATE These aren’t my favorites, but I believe they’re cheap given the current prices. I think the whale sold AI stocks and is now looking into small-cap undervalued stocks. It’s a slo, but I think it’ll move soon. mall bet here.
1 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Jan. 14 at 2:21 PM
$FATE and $TCRX both are way under cash. $XBI has moved up in last 2 months yet above two stocks not much gain so far.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 14 at 2:28 AM
$FATE This one's been bouncing around a bit lately. It hit a high around $1.70 and dipped to a low near $0.65. Currently holding steady around $1.02 with average volume around 1.9 million.
0 · Reply
Southshd
Southshd Jan. 13 at 8:05 PM
$FATE Grabbed another 25k shares today! 225k shares long and strong! 2026 could be a great year for bio stocks, several with decent balance sheets have already started to move in a positive direction. Holding 200k of Allo as well which has had a nice run the past few weeks hopefully Fate will follow! GL fellow longs!
1 · Reply
cta7978
cta7978 Jan. 13 at 2:55 PM
$FATE
1 · Reply
DarkSonar
DarkSonar Jan. 13 at 3:03 AM
$FATE This is a wonderful little stockity stock. Keep an eye on this because is primed for a move up!! 🧨
2 · Reply
Nik7777
Nik7777 Jan. 13 at 12:08 AM
$FATE https://www.marketbeat.com/instant-alerts/insider-selling-fate-therapeutics-nasdaqfate-insider-sells-10589-shares-of-stock-2026-01-12/#google_vignette
1 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Jan. 12 at 8:51 PM
$TCRX and $FATE nice recovery.. these can move much higher in coming weeks
0 · Reply
Invest2live
Invest2live Jan. 12 at 8:47 PM
$IPSC 293% already; congrats 🌿🎈🌿 Checkout $FATE and $RXRX; undervalued
0 · Reply
DarkSonar
DarkSonar Jan. 12 at 8:36 PM
$FATE Have to do a deeper research on this little stock but it looks fantastic!!! Fighting to keep above $1.00. Loving the technicals. Monitoring. 🔬
0 · Reply
GangsterX
GangsterX Jan. 12 at 7:35 PM
$FATE $PMVP It’s not my favorite, but I think it will go up. It’s slow, though. My favorite is still ALLO.
0 · Reply
Rocketman808
Rocketman808 Jan. 12 at 7:31 PM
$FATE boring days only last so long, take advantage
0 · Reply
GangsterX
GangsterX Jan. 12 at 7:09 PM
$FATE Filled 1.05. Small bet ok..I need to grab all huge cash low debt biotech here. This pig is slow but just wait for the pump.
0 · Reply
cta7978
cta7978 Jan. 12 at 4:32 PM
$FATE
0 · Reply
Nik7777
Nik7777 Jan. 12 at 4:25 PM
$FATE
0 · Reply
W2Cap
W2Cap Jan. 12 at 4:11 PM
$FATE and $HUMA - hoping both have something big to present at the JPM conference. Both wildly undervalued rn.
1 · Reply
StockDaddy68
StockDaddy68 Jan. 12 at 10:47 AM
$FATE Good morning!!!!
0 · Reply
Jake140
Jake140 Jan. 12 at 10:29 AM
$FATE Morning All!
0 · Reply
vivalasvegasal
vivalasvegasal Jan. 11 at 8:05 PM
$FATE just brought a wedge anyway
0 · Reply